W Janni

595 total citations
72 papers, 449 citations indexed

About

W Janni is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, W Janni has authored 72 papers receiving a total of 449 indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Oncology, 36 papers in Pulmonary and Respiratory Medicine and 34 papers in Cancer Research. Recurrent topics in W Janni's work include Breast Cancer Treatment Studies (29 papers), Cancer Treatment and Pharmacology (22 papers) and Cancer Cells and Metastasis (21 papers). W Janni is often cited by papers focused on Breast Cancer Treatment Studies (29 papers), Cancer Treatment and Pharmacology (22 papers) and Cancer Cells and Metastasis (21 papers). W Janni collaborates with scholars based in Germany, France and Poland. W Janni's co-authors include Klaus Pantel, Harald Sommer, Brigitte Rack, G. Riethmüller, F. Hepp, F Willgeroth, Stephan Braun, Christian Schindlbeck, Ulrich Andergassen and B. Strobl and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

W Janni

63 papers receiving 437 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
W Janni Germany	10	363	193	119	86	58	72	449
Małgorzata Banyś Germany	18	584 1.6×	333 1.7×	148 1.2×	64 0.7×	121 2.1×	32	714
M. Combe France	11	249 0.7×	110 0.6×	83 0.7×	79 0.9×	76 1.3×	22	477
P. Hirnle Germany	11	250 0.7×	63 0.3×	110 0.9×	108 1.3×	91 1.6×	31	454
F Willgeroth Germany	6	376 1.0×	209 1.1×	94 0.8×	40 0.5×	87 1.5×	17	503
Hyung‐Sik Lee South Korea	10	176 0.5×	99 0.5×	105 0.9×	56 0.7×	70 1.2×	26	362
Carmen Calfa United States	10	294 0.8×	131 0.7×	140 1.2×	45 0.5×	76 1.3×	40	406
Mitsuo Terada Japan	11	239 0.7×	140 0.7×	81 0.7×	64 0.7×	112 1.9×	36	402
Brittany Arnold United States	8	265 0.7×	198 1.0×	99 0.8×	48 0.6×	24 0.4×	15	427
M Harrison United States	7	199 0.5×	103 0.5×	83 0.7×	224 2.6×	22 0.4×	9	488
Colin M. Court United States	13	383 1.1×	274 1.4×	99 0.8×	20 0.2×	140 2.4×	37	573

Countries citing papers authored by W Janni

Since Specialization

Citations

This map shows the geographic impact of W Janni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by W Janni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites W Janni more than expected).

Fields of papers citing papers by W Janni

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by W Janni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by W Janni. The network helps show where W Janni may publish in the future.

Co-authorship network of co-authors of W Janni

This figure shows the co-authorship network connecting the top 25 collaborators of W Janni. A scholar is included among the top collaborators of W Janni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with W Janni. W Janni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mayer, E., W Janni, X. Cynthia, et al.. (2025). 486MO Patient-reported outcomes (PROs) from the SERENA-6 trial of camizestrant (CAMI) + CDK4/6 inhibitor (CDK4/6i) for emergent ESR1m during first-line (1L) endocrine-based therapy and ahead of disease progression in patients (pts) with HR+/HER2– advanced breast cancer (ABC). Annals of Oncology. 36. S379–S379. 1 indexed citations

Ignatiadis, Michail, Emmanouil Saloustros, Ciara M. Kelly, et al.. (2024). 338TiP EORTC-2129-BCG: Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA). Annals of Oncology. 35. S355–S356. 2 indexed citations

Janni, W, Brigitte Rack, Lothar Häberle, et al.. (2017). Abstract P2-05-02: Active surveillance with a combination of tumor marker CA27.29 and detection of circulating tumor cells two year after primary diagnosis strongly predicts subsequent prognosis. Cancer Research. 77(4_Supplement). P2–5. 1 indexed citations

Andergassen, Ulrich, et al.. (2016). Disseminated and circulating tumor cells in bone marrow and blood of breast cancer patients: properties, enrichment, and potential targets. Journal of Cancer Research and Clinical Oncology. 142(9). 1883–1895. 20 indexed citations

Trapp, Elisabeth, Brigitte Rack, Lothar Häberle, et al.. (2016). Detection of circulating tumor cells during long-term follow-up of high-risk breast cancer patients indicates poor prognosis – results of the adjuvant SUCCESS A trial. Geburtshilfe und Frauenheilkunde. 76(10). 1 indexed citations

Banyś, Małgorzata, Erich‐Franz Solomayer, Gerhard Gebauer, et al.. (2013). Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial. Senologie - Zeitschrift für Mammadiagnostik und -therapie. 10(2). 2 indexed citations

Janni, W, Volkmar Müller, Andreas Schneeweiß, et al.. (2012). 191 DETECT III – a Multicenter, Randomized, Phase III Study to Compare Standard Therapy Alone Versus Standard Therapy Plus Lapatinib in Patients with Initially HER2-negative Metastatic Breast Cancer and HER2-positive Circulating Tumor Cells. European Journal of Cancer. 48. S95–S96. 5 indexed citations

Sommer, H., et al.. (2011). P277 Simultaneous study of docetaxel based anthracycline free adjuvant treatment evaluation, as well as life style intervention strategies: The German SUCCESS C trial. The Breast. 20. S66–S66. 1 indexed citations

Beckmann, MW, et al.. (2011). The SUCCESS-C trial: Interim analysis of toxicity evaluating the role of an anthracycline-free chemotherapy regimen in the adjuvant treatment of HER2/neu-negative breast cancer.. Journal of Clinical Oncology. 29(15_suppl). 1070–1070. 1 indexed citations

10.

Látó, Krisztián, et al.. (2011). Fetal Gastroschisis: A Comparison of Second vs. Third-Trimester Bowel Dilatation for Predicting Bowel Atresia and Neonatal Outcomes. Ultraschall in der Medizin - European Journal of Ultrasound. 34(2). 157–161. 11 indexed citations

11.

Schindlbeck, Christian, J Jueckstock, Andreas Schneeweiß, et al.. (2009). Prognostic relevance of circulating tumor cells (CTCs) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy – translational research program of the German SUCCESS-trial.. Cancer Research. 69(2_Supplement). 303–303. 4 indexed citations

12.

Solomayer, Erich‐Franz, Gerhard Gebauer, P. Hirnle, et al.. (2009). Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients.. Cancer Research. 69(2_Supplement). 2048–2048. 55 indexed citations

13.

Rack, Brigitte, Christian Schindlbeck, B. Strobl, et al.. (2008). Zoledronsäure bei persistierenden isolierten Tumorzellen im Knochenmark bei Mammakarzinom. DMW - Deutsche Medizinische Wochenschrift. 133(7). 285–289. 21 indexed citations

14.

Janni, W, Nadia Harbeck, Brigitte Rack, et al.. (2007). Final toxicity analysis of the ADEBAR phase III study evaluating the role of docetaxel in the adjuvant therapy of breast cancer patients with extensive lymph node involvement. mediaTUM (Technical University of Munich). 1 indexed citations

15.

Strobl, B., et al.. (2004). Whole body hyperthermia combined with carboplatin/ paclitaxel in patients with ovarian carcinoma –Phase-II-study. Journal of Clinical Oncology. 22(14_suppl). 5128–5128. 2 indexed citations

16.

Janni, W, et al.. (2002). Der Einfluss des Hämoglobinwertes auf die hämatogene Tumorzelldisseminierung zum Zeitpunkt der Primärdiagnose des Mammakarzinoms. DMW - Deutsche Medizinische Wochenschrift. 127(3). 71–77. 2 indexed citations

17.

Schindlbeck, Christian, et al.. (2002). [Tumor biology of primary breast cancer and minimal residual disease].. PubMed. 59. 27–31. 2 indexed citations

18.

Janni, W, Th. Dimpfl, D. Rjosk, et al.. (2001). Matched pair analysis of survival after chest-wall recurrence compared to mammary recurrence: a long-term follow-up. Journal of Cancer Research and Clinical Oncology. 127(7). 455–462. 11 indexed citations

19.

Janni, W, et al.. (1999). Prognostic value of cytokeratin (CK)-positive bone marrow micrometastsaes (BMM) detected in high-risk breast cancer patients after adjuvant chemotherapy. European Journal of Cancer. 35. S159–S159. 1 indexed citations

20.

Janni, W, S. Braun, F. Hepp, et al.. (1998). Potential clinical relevance of micrometastatic breast cancer. 39. 566. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact